경구 당뇨병 치료제 시장 규모 : 약물 유형별, 최종 사용자별, 유통 채널별, 지역별 및 예측별

Global Oral Anti-Diabetic Drug Market Analysis

According to Verified Market Research, the Global Oral Anti-Diabetic Drug Market size was valued at USD 64.5 billion in 2025 and is estimated to reach USD 98.2 billion by 2033, growing at a CAGR of 5.8% from 2027 to 2033.

The global oral antidiabetic drugs market is expected to witness significant growth during the forecast period. Increasing cases of type 2 diabetes boosts the oral antidiabetic drugs market. The adaptation of unhealthy lifestyle, environment pollution and family history with diabetes disease also boost up the oral antidiabetic drugs market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.

Global Oral Anti-Diabetic Drug Market Definition

Diabetes is a type of disease with high glucose level in the blood resulting deficiency of insulin in the body. Drugs which are used for the treatment of diabetes called as antidiabetic drugs. It reduces blood glucose level by activation of glycogen phosphorylase, and gluconeogenic enzymes, revealed decreased rates of glycogenolysis and gluconeogenesis. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Oral Anti-Diabetic Drug Market Overview

The oral medications used to manage and control blood glucose levels in patients with Type 2 Diabetes and, in some cases, Type 1 Diabetes. These drugs include classes such as biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and alpha-glucosidase inhibitors that help regulate insulin sensitivity, reduce glucose production, or enhance glucose excretion. The market is driven by the rising global prevalence of diabetes, aging populations, sedentary lifestyles, and increasing obesity rates. Additionally, advancements in drug formulations, fixed-dose combination therapies, and improved access to healthcare services are supporting market expansion, while pharmaceutical companies continue investing in research and development to introduce more effective and patient-friendly oral therapies.

Global Oral Anti-Diabetic Drug Market: Segmentation Analysis.

The Global Oral Anti-Diabetic Drug Market is segmented based on Drug Class, End user, Distribution Channel and Geography.

Oral Anti-Diabetic Drug Market, By Drug Class

Biguanides

Thiazolidinediones

Dipeptidyl Peptidase IV Inhibitors, a-Glucosidase Inhibitors

Insulin Secretagogues

Amylin Analog

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

Glucagon-Like Peptide-1 Receptor Agonists

Others

Biguanides such as Metformin are widely used as first-line therapy for managing Type 2 Diabetes, while other drug classes help improve insulin sensitivity, stimulate insulin secretion, or reduce glucose absorption and excretion, offering diverse treatment options for blood glucose control.

Oral Anti-Diabetic Drug Market, By End User

Hospitals

Homecare

Specialty Centres

Others

Hospitals remain a key segment due to advanced treatment and monitoring facilities, while homecare is expanding as many patients manage diabetes with long-term oral medications at home. Specialty centres, including diabetes clinics, provide focused care, disease management programs, and patient education.

Oral Anti-Diabetic Drug Market, By Distribution Channel

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Retail pharmacies hold a major share due to easy accessibility of diabetes medications, while hospital pharmacies supply drugs during clinical treatment. Online pharmacies are gaining popularity as they provide convenient purchasing options and home delivery for patients requiring regular medication refills.

Oral Anti-Diabetic Drug Market, By Geography

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Based on Geography, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America is expected to have the highest market growth due to rapidly increasing smoking & obesity population and presence of key manufacture of the product. Asia-Pacific dominates the market due to enhanced prevalence of diabetes and related disorders and number of generic drugs.

Key Players

The Global Oral Anti-Diabetic Drug Market is highly fragmented with the presence of a large number of players. Some of the major companies include Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.S.), Bayer AG (Germany).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET OVERVIEW
• 3.2 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ATTRACTIVENESS ANALYSIS, BY DRUG CLASS
• 3.8 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ATTRACTIVENESS ANALYSIS, BY DISTRIBUTION CHANNEL
• 3.9 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET ATTRACTIVENESS ANALYSIS, BY END USER
• 3.10 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET, BY DRUG CLASS (USD BILLION)
• 3.12 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET, BY DISTRIBUTION CHANNEL (USD BILLION)
• 3.13 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET, BY END USER(USD BILLION)
• 3.14 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET EVOLUTION
• 4.2 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE PRODUCTS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY DRUG CLASS

• 5.1 OVERVIEW
• 5.2 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DRUG CLASS
• 5.3 BIGUANIDES
• 5.4 THIAZOLIDINEDIONES
• 5.5 DIPEPTIDYL PEPTIDASE IV INHIBITORS, A-GLUCOSIDASE INHIBITORS
• 5.6 INSULIN SECRETAGOGUES
• 5.7 AMYLIN ANALOG
• 5.8 SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS
• 5.9 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

6 MARKET, BY END USER

• 6.1 OVERVIEW
• 6.2 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USER
• 6.3 HOSPITALS
• 6.4 HOMECARE
• 6.5 SPECIALTY CENTRES
• 6.6 OTHERS

7 MARKET, BY DISTRIBUTION CHANNEL

• 7.1 OVERVIEW
• 7.2 GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DISTRIBUTION CHANNEL
• 7.3 HOSPITAL PHARMACY
• 7.4 ONLINE PHARMACY
• 7.5 RETAIL PHARMACY

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.3 KEY DEVELOPMENT STRATEGIES
• 9.4 COMPANY REGIONAL FOOTPRINT
• 9.5 ACE MATRIX
  • 9.5.1 ACTIVE
  • 9.5.2 CUTTING EDGE
  • 9.5.3 EMERGING
  • 9.5.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 PFIZER INC (U.S.)
• 10.3 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
• 10.4 MYLAN N.V. (U.S.)
• 10.5 FRESENIUS KABI AG (GERMANY)
• 10.6 HIKMA PHARMACEUTICALS PLC (U.K.)
• 10.7 NOVARTIS AG (SWITZERLAND)
• 10.8 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
• 10.9 BRISTOL MYERS SQUIBB COMPANY (U.S.) GSK PLC. (U.S.)
• 10.10 BAYER AG (GERMANY).